OpenBilldrug price receipt

NADAC week of 2026-10-14

DABIGATRAN ETEXILATE 150 MG CP

For 30 capsules

Pharmacies pay

$23.84 filed

30 × $0.79456 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$67.40 filed

30 × $2.24667 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

2.8× estimated

Medicare paid 2.8× what pharmacies pay.

Part D averages every strength and form sold under “Dabigatran Etexilate” / “Dabigatran Etexilate Mesylate” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$32.42 estimated

$23.84 + $3.58 (15%) + $5.00 fee per fill = $32.42

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

DABIGATRAN ETEXILATE 150 MG CP is how the CMS NADAC file names this product. The FDA NDC Directory lists it as dabigatran etexilate, under the trade name “DABIGATRAN”.

FDA gives its dosage form as “capsule” and “capsule, coated pellets” and its route as oral.

FDA lists 11 labelers (the companies named on the label) for its NDCs, among them Mylan Pharmaceuticals Inc., Major Pharmaceuticals and Camber Pharmaceuticals, Inc.

FDA’s Established Pharmacologic Class for it is Direct Thrombin Inhibitor.

The NADAC file of 2026-10-14 prices it under 16 NDCs (National Drug Codes); the FDA directory lists 14 of them.

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $23.84 for 30 capsules (30 × $0.79456 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

The 11 labelers

LabelerNDCsPharmacies pay per unit
Alembic Pharmaceuticals Inc.2$0.79456 per EA filed
Camber Pharmaceuticals, Inc.2$0.79456 per EA filed
Major Pharmaceuticals2$0.79456 per EA filed
American Health Packaging1$0.79456 per EA filed
Apotex Corp.1$0.79456 per EA filed
Ascend Laboratories, LLC1$0.79456 per EA filed
Aurobindo Pharma Limited1$0.79456 per EA filed
Dr.Reddys Laboratories Inc1$0.79456 per EA filed
Mylan Pharmaceuticals Inc.1$0.79456 per EA filed
NorthStar RxLLC1$0.79456 per EA filed
Novadoz Pharmaceuticals LLC1$0.79456 per EA filed
Not listed as a package in the FDA directory2$0.79456 per EA filed
All 16 NDCs, with labeler and price
  • 00378-0266-91 · Mylan Pharmaceuticals Inc. · $0.79456 per EA · eff. 2026-09-23 filed
  • 00904-7255-10 · Major Pharmaceuticals · $0.79456 per EA · eff. 2026-09-23 filed
  • 00904-7255-35 · not listed as a package in the FDA directory · $0.79456 per EA · eff. 2026-09-23 filed
  • 00904-7255-68 · Major Pharmaceuticals · $0.79456 per EA · eff. 2026-09-23 filed
  • 31722-0622-32 · Camber Pharmaceuticals, Inc. · $0.79456 per EA · eff. 2026-09-23 filed
  • 31722-0622-60 · Camber Pharmaceuticals, Inc. · $0.79456 per EA · eff. 2026-09-23 filed
  • 43598-0641-60 · Dr.Reddys Laboratories Inc · $0.79456 per EA · eff. 2026-09-23 filed
  • 59651-0975-60 · Aurobindo Pharma Limited · $0.79456 per EA · eff. 2026-09-23 filed
  • 60505-4348-06 · Apotex Corp. · $0.79456 per EA · eff. 2026-09-23 filed
  • 60687-0974-32 · American Health Packaging · $0.79456 per EA · eff. 2026-09-23 filed
  • 60687-0974-33 · not listed as a package in the FDA directory · $0.79456 per EA · eff. 2026-09-23 filed
  • 62332-0636-06 · Alembic Pharmaceuticals Inc. · $0.79456 per EA · eff. 2026-09-23 filed
  • 62332-0636-60 · Alembic Pharmaceuticals Inc. · $0.79456 per EA · eff. 2026-09-23 filed
  • 67877-0475-60 · Ascend Laboratories, LLC · $0.79456 per EA · eff. 2026-09-23 filed
  • 72205-0204-60 · Novadoz Pharmaceuticals LLC · $0.79456 per EA · eff. 2026-09-23 filed
  • 72603-0239-01 · NorthStar RxLLC · $0.79456 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

2 other products in the NADAC file share the FDA nonproprietary name dabigatran etexilate with DABIGATRAN ETEXILATE 150 MG CP.

ProductPharmacies pay per unitMedicare per unit
DABIGATRAN ETEXILATE 75 MG CAP
generic · capsule / capsule, coated pellets
$0.75027 per EA filed
eff. 2026-09-23
$2.24667 per EA filed
Part D 2024 average
DABIGATRAN ETEXILATE 110 MG CP
generic · capsule, coated pellets / capsule
$0.93752 per EA filed
eff. 2026-09-23
$2.24667 per EA filed
Part D 2024 average
DABIGATRAN ETEXILATE 150 MG CP this page
generic · capsule / capsule, coated pellets
$0.79456 per EA filed
eff. 2026-09-23
$2.24667 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 16 NDCs’ NADAC prices is $0.79456 per EA filed.

Of the 5 other products in FDA’s Direct Thrombin Inhibitor class priced per EA, 4 have a higher middle NADAC price and 1 a lower one. The one in the middle is PRADAXA 150 MG CAPSULE, at $3.1597 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $67.40 for 30 capsules, at an average of $2.24667 per EA in 2024 (2024-01-01 to 2024-12-31) for “Dabigatran Etexilate” and “Dabigatran Etexilate Mesylate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 299,692 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for DABIGATRAN ETEXILATE 150 MG CP labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Dabigatran Etexilate / Dabigatran Etexilate Mesylate: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on generic name.